Idera Pharmaceuticals, Inc.
(NASDAQ : IDRA)

( )
IDRA After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
1.08%196.181.2%$557.67m
TSROTESARO, Inc.
0.22%74.2514.4%$534.38m
CELGCelgene Corporation
1.18%69.491.2%$528.88m
GILDGilead Sciences, Inc.
0.34%67.720.9%$508.18m
BIIBBiogen Inc.
0.11%319.791.3%$358.06m
ILMNIllumina, Inc.
1.81%328.903.5%$353.03m
REGNRegeneron Pharmaceuticals, Inc.
-0.50%375.722.6%$262.39m
AAgilent Technologies, Inc.
0.67%71.061.5%$237.22m
VRTXVertex Pharmaceuticals Incorporated
-0.32%173.231.9%$235.67m
ALXNAlexion Pharmaceuticals, Inc.
0.16%114.832.0%$143.36m
SRPTSarepta Therapeutics, Inc.
1.79%125.0015.4%$112.54m
INCYIncyte Corporation
0.28%65.602.5%$104.06m
EXASExact Sciences Corporation
-0.04%69.5225.3%$99.67m
NKTRNektar Therapeutics
-0.63%36.435.5%$97.21m
EXELExelixis, Inc.
-1.78%20.986.4%$82.17m

Company Profile

Idera Pharmaceuticals, Inc. is a clinical stage biotechnology company, which focuses on the discovery, development and commercialization of novel oligonucleotide therapeutics for oncology and rare diseases. The firm uses two distinct proprietary drug discovery technology platforms to design and develop drug candidates: Toll-like receptor targeting technology and third-generation antisense technology. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Cambridge, MA.